April 11th 2024
In an interview with Targeted Oncology, Sara Kerr, MD discussed the evolution of genomic testing for patients with cancer and highlighted the program used at Allina Health.
February 14th 2024
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
In-House Molecular Profiling Becomes Increasingly Important for Lung Cancers
June 13th 2019Timothy F. Burns, MD, PhD, discusses the value of conducting next-generation sequencing in-house for patients with lung cancer compared with sending out to an external laboratory for molecular profiling results. Burns says he conducts NGS testing on all patients with metastatic and nonsquamous lung cancers. This includes patients that are both smokers and non-smokers.
Watch
Genomic Testing and Targeted Therapies May be Underused in Community Practice, Study Shows
June 13th 2019A review of patients with advanced non–small cell lung cancer treated in a community practice setting demonstrated that not all patients recommended for receiving genomic testing are being appropriately tested for potential genetic drivers of disease.<br />
Read More
Burris Calls for Greater Adoption of NGS by Community Oncologists
June 12th 2019The development and advancements in targeted therapies and immunotherapies have dramatically changed drug development and clinical practice. With access to widespread genomic research and next-generation sequencing, details about somatic and germline mutations in solid tumors can better inform the treatment plan, Howard “Skip” Burris III, MD, explains.
Read More
Expert Discusses Role of Genetic Testing in Detection and Prevention of Pancreatic and Other Cancers
May 21st 2019Jennifer Geurts, MS, CGC, discusses the current role of genetic testing, both in patients diagnosed with cancer, as well as family members that could be at risk of developing cancer. She also highlights how genetic counseling can impact treatment decisions in patients with pancreatic, breast, and ovarian cancers.
Read More
Arun Highlights Importance of Identifying BRCA1/2 Mutations in Metastatic Breast Cancer
May 14th 2019In an interview with <em>Targeted Oncology</em>, Banu Arun, MD, discussed the role of genetic testing in patients with metastatic breast cancer. She highlighted the importance of identifying various mutations, including <em>BRCA1/2 </em>mutations in light of the approval of PARP inhibitors. In addition, she spoke to how the role of genomic testing is evolving in this field with the development of new targeted agents.
Read More
Genomic Profiling in Sarcoma Shows Potential in Guiding Clinical Management
May 2nd 2019A new single-center report has found that the results of next-generation sequencing–based molecular profiling for non–GI stromal tumor sarcomas provided information used to effectively guide clinical management.
Read More
Significantly higher response rates were seen in patients with <em>ALK</em>-positive non–small cell lung cancer who had been treated with at least 1 prior ALK tyrosine kinase inhibitor before receiving lorlatinib and who harbored an <em>ALK </em>resistance mutation compared with those who did not have an <em>ALK </em>mutation.
Read More
Study Finds Extended-Release Anagrelide Noninferior to Reference Product in ET
April 16th 2019A new phase III trial has demonstrated that a novel extended-release formulation of anagrelide (Thromboreductin) is noninferior to immediate-release anagrelide in reducing platelet counts in patients with essential thrombocythemia.
Read More
Investigators Work to Identify Genomic Correlates of Response to Immunotherapy
April 3rd 2019At the 2019 American Society of Clinical Oncology–Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium, Natalie Vokes, MD, MPhil, reviews the latest evidence linking tumor mutational burden to outcome in patients treated with immune checkpoint blockade as well as genomic correlates of response within the tumor immunity cycle.
Read More
NGS Testing of HCC Reveals Potential Biomarkers and Mutations for Treatment Matching
March 29th 2019An analysis of the genotyping of tumor tissue samples from patients with hepatocellular carcinoma identified frequent alterations and potentially actionable mutations in cases of HCC, and helped to confirm the clinical utility of next-generation sequencing testing for matching patients to targeted therapies and immunotherapies.
Read More
VA Broadens Comprehensive Care by Providing Genomic Testing in Advanced Cancer
March 8th 2019Genomic testing could increasingly be utilized to guide treatment decisions for Veteran patients with cancer. Two recent announcements confirm an emerging focus from Veterans Affairs on genetic testing that provides more informed and tailored cancer care for US Veterans.
Read More
CMS Overlooks Early-Staged Cancer in National Coverage Determination for NGS-Based Testing
February 6th 2019Over 60 healthcare organizations are pressing the Center for Medicare and Medicaid Services to revise its current interpretation of the National Coverage Determination, which they say wrongly excludes germline next-generation sequencing-based testing from Medicare coverage for patients with early-stage cancers.<br />
Read More
Broad-Panel NGS Benefits Metastatic NSCLC
January 11th 2019Increasing clinical relevance of less common gene signatures and alterations is leading to a benefit from broad-panel next-generation sequencing testing for patients with metastatic non–small cell lung cancer, according to an expert at Memorial Sloan Kettering Cancer Center.
Read More
Integrating Molecular Pathology Into NSCLC Treatment Selection
July 28th 2018Ignacio I. Wistuba, MD, Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, discusses how clinicians can best integrate molecular pathology into their treatment selection for patients with non-small cell lung cancer.
Watch